A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to
evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of
treatment in patients with treatment-resistant hypertension (rHTN).